INTRODUCTION
============

MS (multiple sclerosis) is a chronic autoimmune demyelinating and neurodegenerative disorder of the CNS (central nervous system), afflicting over two-and-a-half million people worldwide, with women affected three times more frequently than men. MS is characterized by an extensive and complex immune response, demyelination, glial scarring (sclerosis), perivascular leucocyte infiltration, and oligodendrocyte and axonal loss ([@B165]). Being the most common cause of neurological disability in young adults, it represents a prototypic autoimmune inflammatory disorder of the CNS. Although the agent(s) that initiate disease onset have not been clearly elucidated, several lines of evidence, derived from the EAE (experimental autoimmune encephalomyelitis) model, support that the disease is autoimmune in nature, regulated by APCs (antigen-presenting cells) and auto-reactive Th1 and Th17 cells ([@B191]; [@B187]; [@B122]). These cell types co-ordinate the production of inflammatory cytokines and chemokines within the CNS parenchyma, leading to the recruitment of macrophages, mast cells, neutrophils, CD8^+^ T-cells and B-cells, which subsequently attack components of the CNS, including the myelin sheath and axons ([@B183]). The accumulation of axonal damage leads to a permanent loss of neurological function ([@B128]).

Given that a pathological hallmark of MS is an overactive immune response, strategies for the treatment of MS have focused on suppressing inflammation, resulting in an emergence of DMDs (disease-modifying drugs). As reviewed in [@B9] and [@B68], four approved DMDs are currently available which target the immune system. They include recombinant IFNβ1a (interferon β1a), IFNβ1b (The [@B200]; [@B111]; [@B171]) and glatiramer acetate ([@B76]; [@B32]; [@B72]) as first-line treatments, with mitoxantrone ([@B67]; [@B101]; [@B129]) reserved as a second-line therapy due to its association with cardiomyopathy, leukaemia, leucopenia, and infection ([@B9]; [@B68]). Unfortunately, the efficacy of the DMDs appears to be modest. Indeed, they are able to delay MS relapse and slow disease progression for RRMS (relapsing-remitting multiple sclerosis), but fail to show significant benefit in progressive forms of MS such as SPMS (secondary progressive form of MS) and PPMS (primary progressive form of MS) ([@B86]; [@B186]; [@B144]).

Currently, only injectable drugs are available for the treatment of MS. Therefore emerging oral therapies for MS are an especially attractive alternative to current DMDs. As they do not rely on injections, they are convenient in use, hence the hope for a much better compliance. Thus, much attention has centred around four emerging oral formulations, cladribine, laquinimod, fingolimod and dalfampridine ([@B73]; [@B135]). These have demonstrated impressive efficacy in terms of clinical outcomes ([@B169]; [@B116], [@B117]; [@B73]; [@B79]; [@B135]). Interestingly, unlike the other agents, the mechanism of action of dalfampridine which is a selective potassium channel blocker, does not rely on immunomodulation but rather on restoring the conduction of injured axons ([@B114]). Thus, dalfampridine is indicated as a symptomatic therapy to improve walking in MS patients ([@B114]; [@B87]), but is not necessarily efficacious in other domains of MS. However, as reviewed in [@B135] and in [@B73], there are a multitude of tolerable and/or serious adverse effects associated with each of these drugs. At present, laquinimod and fingolimod have received fast-track review status from the FDA (Food and Drug Administration); they may reach the market in late 2011. In contrast, cladribine and dalfampridine are still in the FDA\'s approval review for MS. Based on their side effect profiles and the unknown long-term safety outcomes, it remains to be seen whether these emerging DMDs will allow them to displace existing first-line therapies.

Although these current and emerging drugs provide benefit for MS, especially in the early phases of the disease, existing drugs have little effect on the neurodegenerative component that occurs at a secondary stage of the disease. Thus, the development of effective therapy for slowing down the course of SPMS and PPMS has been and remains challenging. Stem cell therapy has shown some benefit, but this therapy is still investigational and controversial. For example, due to their potent immune regulatory, neuroprotective properties, and capability to home to inflammatory or injured sites ([@B74]; [@B119]), MSCs (mesenchymal stem cells) have recently emerged as a promising alternative for the treatment of MS (reviewed in [@B184]). The therapeutic efficacy of MSCs has also been established in EAE. Systemic transplantation of autologous or allogeneic MSCs in relapsing remitting ([@B78]) or chronic progressive models of EAE ([@B224]) has shown that MSCs are efficacious in suppressing clinical EAE disease in the early stages of disease onset, limiting the number of CNS inflammatory lesions, reducing axonal loss and preserving myelin structure ([@B224]; [@B78]). Despite these positive outcomes, solid data regarding the safety of MSCs in MS are still lacking. In addition, because of their ability to suppress immune responses, adverse effects such as immune deficiency leading to infection, activation of tumour growth and metastasis must be ruled out ([@B64]; [@B118]; [@B217]).

While having moderate success in slowing the progression of disability as well as reducing the severity and frequency of exacerbations of MS, the fact remains that these treatment modalities do not cure the disease. As such, the need for innovative approaches becomes of paramount importance. In this respect, VIP (vasoactive intestinal peptide) and PACAP (pituitary adenylate cyclase-activating peptide), two highly homologous neuroprotective peptides initially characterized as neuropeptide neurotransmitters, have recently been found to show pronounced anti-inflammatory actions when administered systemically in animal models of inflammatory disease, including EAE ([@B3], [@B2]; [@B44]; [@B120]; [@B84]). The immunosuppressive effects of these peptides have, in the past, been attributed to their capacities to modulate macrophage and DC (dendritic cell) function and to inhibit antigen-specific Th1-driven responses ([@B57]). While these mechanisms may be relevant in EAE and other inflammatory diseases, other evidence as well as our data indicate that these peptides may modulate the production and/or activities of Treg (regulatory T) and Th17 cells ([@B37]; [@B113]; [@B69]). Thus, because VIP and PACAP are potent anti-inflammatory factors and because their receptors are widely distributed in the immune system, VIP and PACAP have recently emerged as candidates for the treatment of MS as well as other inflammatory diseases. In this review, we will concentrate our discussion on VIP, PACAP and their receptors and provide an overview of what it is currently known and accepted concerning the structure of both peptides and their respective targets, the signalling pathways involved and their biological functions with a focus on the immunomodulatory and neuroprotective actions. Finally to guide investigators towards drug design and new therapeutic pathways that can be exploited in MS and other inflammatory diseases, we will describe structure--activity relationship data and biophysical studies that probe the interaction between VIP/PACAP and their cognate receptors at the molecular level.

VIP AND PACAP BACKGROUND
========================

Isolated in porcine duodenum by [@B178], VIP is a neuropeptide of 28 amino acids. Almost 20 years later, PACAP was isolated from ovine hypothalamus extracts on the basis of its ability to stimulate the production of cAMP in cultured pituitary cells ([@B145]). Furthermore, PACAP exists in two forms as PACAP38 (38 amino acid residues) and PACAP27 that corresponds to the N-terminal 27 residues of PACAP38 ([@B145], [@B146]). Both forms were found to be generally equipotent in receptor binding and AC (adenylate cyclase) assays in some cells ([@B28]; [@B146]). VIP and PACAP exhibit very high similarity with 68% sequence identity and belong to the secretin/VIP peptide family as discussed below in more detail in the section titled 'Structural and functional properties'.

VIP and PACAP actions are mediated through heterotrimeric GPCRs (G-protein-coupled receptors). Three VIP/PACAP receptor genes have been cloned ([@B126]; [@B63]; [@B208]). The *VIPR1* and *VIPR2* genes encode receptors that respond equally to VIP and PACAP named VPAC1 and VPAC2 respectively ([@B110]; [@B137]; [@B190]; [@B34]), whereas the *ADCYAP1R* gene encodes the PACAP-preferring receptor PAC1 ([@B102]; [@B106]; [@B168]). In mammals, both peptides are widely expressed in the central and peripheral nervous systems ([@B170]; [@B126]; [@B63]; [@B208]), are also produced within immune cells where they play the role of a 'cytokine-like peptide' ([@B82]; [@B57]), and are induced in both neurons and immune cells during inflammation ([@B81]; [@B75]; [@B130]; [@B225]; [@B206]; [@B4]; [@B7]; [@B57]; [@B126]; [@B208]). Likewise, their receptors are mainly distributed in the nervous, endocrine and immune systems ([@B57]; [@B126]; [@B208]). In consonance with this large distribution, they are pleiotropic neuropeptides involved in many physiological and pathophysiological processes ([@B208]) and will be discussed in particular with respect to MS-relevant actions in the 'Potent immunomodulatory actions of VIP and PACAP' section.

STRUCTURAL AND FUNCTIONAL PROPERTIES
====================================

VIP and PACAP
-------------

VIP and PACAP belong to the amidated VIP/secretin family that adopts common properties: (i) a length of 27--44 amino acid residues, (ii) an α-helical configuration along the sequence from residue 6 to the C-terminal end of the peptide, and a non-structured N-terminal end ([@B98]; [@B177]; [@B201]; [@B164]; [@B109]; [@B198]) and (iii) the presence of a common N-terminal structural motif, named N-cap ([@B155]). Utilizing CD spectroscopy and/or NMR spectroscopy, it has been reported that most of the VIP-28 amino acid sequences have an α-helical structure (sequence 7--28) with the exception of the N-terminal 1--5 sequence that has no defined structure in solution when unbound to the receptor ([@B198]) ([Figure 1](#F1){ref-type="fig"}), whereas PACAP27 peptide is characterized by a disordered N-terminal domain consisting of eight amino acids, followed by an α-helical structure ([@B109]; [@B18]). In addition, the conformation of PACAP38 mirrors that of PACAP27 with the C-terminal 28--38 short helix connected by a flexible hinge to the 1--27 region ([@B220]). Furthermore, it is also widely agreed that the disorganized N-terminal 1--5 segment plays a crucial role in activation of AC ([@B126]; [@B208]). Particularly, the N-cap motif was suggested to be involved in receptor activation and may possibly be used for the design of drugs targeting VPAC receptors and other members of the class B GPCRs ([@B155]), while the α-helical conformation is mainly involved in the peptide binding and receptor specificity ([@B126]; [@B208]).

![A 3-D ribbon representation of VIP interaction with the VPAC1 N-terminal domain\
The VPAC1 receptor N-terminal domain encompassing sequence 44--137 is shown in light grey. The structure reveals a Sushi domain characterized by two anti-parallel β-sheets named β1, β2, β3 and β4. Most of the VIP-28 sequence, which is shown in middle grey, has an α-helical structure (sequence 7--28). Photoaffinity labelling experiments showed that Asp^107^, Gly^116^, Cys^122^, Lys^127^ and sequence 129--137 that connects the N^ter^ domain and the first helical TM (shown in *dark grey*) in the N-terminal domain are physically in contact with the side chains of Phe^6^, Tyr^22^, Asn^24^, Asn^28^ and Phe^0^ (shown in dark grey) of VIP respectively. Reprinted from Neuropeptides, 44, A. Couvineau, E. Ceraudo, Y.-V. Tan and M. Laburthe, VPAC1 receptor binding site: contribution of photoaffinity labeling approach, 127--132, © 2010, with permission from Elsevier.](an003e065f01){#F1}

VIP/PACAP receptors, class B GPCRs
----------------------------------

Approx. 20 years ago, VIP and PACAP receptors were designated as VPAC1, VPAC2 and PAC1 receptors by the International Union of Pharmacology according to their relative affinity for their ligands, PACAP and VIP ([@B100]). With the cloning of many other receptors for peptides of the secretin family, a new GPCR subfamily was born and named class B GPCR or class II GPCR or also 'secretin-like' receptor family ([@B126]; [@B208]). Subfamily B GPCRs exhibit 25--50% amino acid identity among themselves and low primary sequence homology with other GPCR classes, but display a common seven TM (transmembrane) helical configuration denoted as TM I to TM VII, which are interconnected by extracellular and intracellular loops ([@B106]; [@B168]; [@B190]; [@B204]; [@B126]; [@B63]; [@B208]). In addition, they exhibit specific features: (i) a relatively large (\>120 residues) N-terminal domain (N^ter^ domain), which is usually smaller in the class A GPCRs or Rhodopsin-like receptors, (ii) six highly conserved cysteine residues forming three disulfide bridges that structure the N^ter^ domain, (iii) the presence of a signal peptide probably involved in addressing the receptor towards the plasma membrane, (iv) several conserved glycosylation sites within the N^ter^ domain involved in receptor trafficking, (v) the absence of archetypical A subfamily GPCR motifs such as E/D-R-Y or NP-xx(x)-Y and (vi) a common but complex gene organization ([@B125], [@B126]).

Molecular anatomy of VIP--PACAP interaction with their receptors
----------------------------------------------------------------

To dissect the binding mechanism between VIP/PACAP and their receptors and particularly to define the residues and structural elements involved, numerous structure--activity relationship experiments have been conducted. These have included chemical modifications, amino acid substitutions, deletion mutagenesis, molecular chimaerisms and photoaffinity labelling analyses as reviewed in [@B126], [@B208] and [@B33]. Interestingly, the data indicate that the N^ter^ domain of the VIP and PACAP receptors is a major binding site, essential for the recognition of their respective ligands ([@B29]; [@B126]; [@B208]; [@B33]; [@B40]). Due to its quite recent recognition, no 3-D structure of a B family receptor is yet available unlike some class A GPCRs. However, the N-terminal domain structures of five type B receptors including human PAC1 receptor ([@B193]) have been determined by NMR spectroscopy or X-ray crystallography. The structures revealed a Sushi domain characterized by two anti-parallel β-sheets (named β1, β2, β3 and β4), and stabilized by three disulfide bonds between six highly conserved cysteine residues and by a putative salt bridge involving acidic and basic residues ([@B95]). This Sushi domain has been shown to play a crucial role in peptide ligand binding ([@B95]). Recently, the development of a structural model of VPAC1 N-terminal domain indicated a structure similar to that of a Sushi domain ([@B198]) ([Figure 1](#F1){ref-type="fig"}).

A detailed molecular description of the interaction of VIP with one of its receptors, VPAC1 receptor, has recently been provided by performing extensive photoaffinity studies ([@B199], [@B197], [@B198]; [@B30]) in which the full-length ligand is covalently bound to its native receptor. This has allowed: (i) analyses of point-to-point interactions between the peptide and its target protein and (ii) the accurate determination of a spatial view of the ligand within the binding site of the receptor. For example, the residues in positions 6, 22, 24 and 28 within the VIP sequence were replaced by a photoreactive Bz-Phe (benzophenone-Phe) amino acid. As illustrated in [Figure 1](#F1){ref-type="fig"}, these studies hence demonstrated that side chains in positions 6, 22, 24 and 28 of VIP are in direct contact with different amino acids in the N^ter^ domain of the receptor e.g. Asp^107^, Gly^116^, Cys^122^ and Lys^127^ respectively ([@B199], [@B197], [@B198]; [@B30]). Based on the four physical interaction sites, identified by the photoaffinity strategy, to the NMR structure of VIP, and the structural model of the VPAC1 N^ter^ domain, the structure of VIP has been docked in the VPAC1 N^ter^ domain. This docking created an accurate 3-D structural model in which the C-terminal segment of the N^ter^ domain of the receptor accommodates the VIP molecule, at least for the 6--28 sequence ([@B199], [@B197], [@B198]; [@B30]) ([Figure 1](#F1){ref-type="fig"}). In parallel, under molecular dynamic simulations in water for over 14 ns, this model exhibited a remarkable stability ([@B30]).

A 'two-site' binding model
--------------------------

The model described above may realistically illustrate the binding between VIP and VPAC1, and potentially explains how the receptor is activated. It is in agreement with the currently accepted concept of a 'two-site' binding model for the interaction of natural ligands to family B GPCRs ([@B105]). In this model, the central and C-terminal α-helical segments of the ligand are trapped by the N^ter^ domain of the receptor. This step positions the disordered N-terminal region of the peptide ligand for its interaction with the TM domain of the receptor to initiate intracellular signalling ([@B105]). In this respect, the integrity of the α-helical conformation seems crucial for the binding of VIP and PACAP to their receptors. Accordingly, deletion in the C-terminal domain of PACAP reduces drastically the binding affinity without altering the propensity of the analogues to activate the receptor at high concentration ([@B17]). Conversely, modifications of the disordered N-terminal portion of PACAP molecule decrease the biological activity of the peptide ([@B161]; [@B18]). In fact, deletion of the entire N-terminal segment, i.e. PACAP(6--38) leads to a potent PAC1/VPAC2 antagonist ([@B205]). It seems clear that the presence of an N-capping signature in the N-terminal end of VIP, PACAP and other members of the VIP/secretin family may contribute to position His^1^ of these peptides into their cognate receptors, triggering the release of the Gαs subunit from the heterotrimeric Gs-protein and activation of AC ([@B155]). Recently, in order to attempt to identify the molecular determinants of VPAC1 involved in the recognition of VIP\'s N-terminal part, photoaffinity labelling experiments have been carried out with a new VIP photoreactive probe containing a Bz-Phe in position 0 ([@B31]). The results revealed that the VIP N-terminal part physically interacts with the receptor domain connecting the N^ter^ domain and the first TM helix ([@B31]) ([Figure 1](#F1){ref-type="fig"}).

Although numerous structure--activity studies and photoaffinity labelling experiments have provided interesting insights to understand the molecular interactions between VIP/PACAP peptides and their receptors, the determination of the structure of the full-length VIP/PACAP receptors clearly remains a major challenge for all investigators in the field, and will facilitate the emergence of new potent drugs.

SIGNALLING PATHWAYS
===================

As discussed earlier, two of the receptors, VPAC1 and VPAC2, recognize PACAP and the related peptide VIP with equally high affinity. The third, PAC1, is a PACAP-preferring receptor. Due to alternative splicing, different PAC1 variants exist and mediate differential coupling to second messengers. Indeed, five variants resulting from alternative splicing in the third intracellular loop region have been identified in rat ([@B188]). These variants are characterized by the absence (short variant, S) or presence of either one or two cassettes of 28 amino acids (hip or hop1 variant) or 27 amino acids (hop2 variant) ([@B188]). Furthermore, the presence of the hip cassette impairs AC stimulation and abolishes PLC (phospholipase C) activation. In addition, a very short splice variant of PAC1, characterized by a 21-amino acid deletion in the N-terminal extracellular domain showed altered selectivities for PACAP38 and PACAP27 isoforms ([@B39]). Another PACAP receptor variant termed as PAC1 TM4 (transmembrane domain 4) has been cloned in the rat cerebellum ([@B35]).

Each of these GPCRs is typically coupled via the heterotrimeric Gs-protein (Gαs) to AC, cAMP production and the PKA (protein kinase A) pathway activation ([@B126]; [@B63]; [@B208]). However, they can couple to other intracellular messenger systems in some cells in parallel or downstream of cAMP including pathways such as nitric oxide ([@B153]), Gαq or Gαi/PLC leading to an increase in the intracellular calcium concentration (\[Ca^2+^\]~i~) and the PKC (protein kinase C) signalling stimulation ([@B188]; [@B63]), PI3K (phosphatidylinositol 3-kinase; [@B192]), src ([@B121]), MAPKs (mitogen-activated protein kinases; [@B8]; [@B212]; [@B132]), Jak/STAT (signal transducer and activator of transcription) and NF-κB (nuclear factor κB; [@B42], [@B43]). Consistent with their diverse biological actions, VIP and PACAP receptor signalling cascades include a constellation of second messengers that are likely dependent not only on the receptor and G-proteins but also on the repertoire of accessory molecules. Thus, besides their interaction with G-proteins, recent results showed that VIP and PACAP receptors were also able to interact with non-G proteins or 'accessory proteins' and to transduce signals independently of the G proteins ([@B195]). The 'accessory protein' group is known to modulate the overall function of the receptors, as extensively demonstrated for the A GPCR subfamily ([@B13]), but poorly documented for the subfamily B GPCRs. For example, a recent report clearly indicated that VPAC1 but not VPAC2 hetero-dimerizes with RAMPs (receptor-activity-modifying proteins) ([@B38]; [@B180]). Particularly, by interacting with RAMP2, VPAC1 induces inositol triphosphate production and increases intracellular calcium without affecting the coupling to AC ([@B38]). Recently, the PDZ domain of S-SCAM (synaptic scaffolding molecule) was found in the VPAC1 receptor C-tail, implying its potential recruitment by S-SCAM to synaptic buds ([@B77]). The latter was reported to result in inhibition of VIP-induced cAMP production and inhibition of agonist-induced internalization of VPAC1 ([@B77]). Besides the role of RAMPs and/or S-SCAM interaction with VPAC1 receptors, one report describes the possible interaction between CaM (calmodulin) and this receptor although the functional role of this interaction remains unclear ([@B138]). Finally, it should be noted that VPAC1 receptor is able to homo-dimerize and hetero-dimerize with VPAC2 or secretin receptors ([@B99]), although again the functional signification remains unclear.

POTENT IMMUNOMODULATORY ACTIONS OF VIP AND PACAP
================================================

VIP, PACAP and their receptors are broadly expressed in the CNS and in most peripheral organs. Given this fact, it is not surprising that these peptides elicit pleiotropic physiological effects ([@B57]; [@B126]; [@B208]). Early reports suggested that VIP and PACAP exerted a multitude of effects on CNS, cardiovascular, circulatory and respiratory systems and on metabolic function ([@B178]; [@B143]; [@B145], [@B146]). Moreover, both peptides have been proposed for the treatment of asthma ([@B97]), impotence ([@B115]), treatment of septic shock ([@B48], [@B57]; [@B139], [@B142]) and diabetes ([@B154]). More recent studies also point to a plethora of putative growth factor-like actions impacting on development and regeneration ([@B93]; [@B41]; [@B181]) and cancer pathogenesis ([@B147]; [@B148]). In the following section, we focus on the immunomodulatory actions of VIP and PACAP ([@B82]; [@B57]; [@B170]; [@B85]). Growth factor-like actions of these peptides are discussed in a subsequent section.

Macrophage function (reviewed in [@B57])
----------------------------------------

Macrophages constitute a major source of chemokines and pro-inflammatory molecules implicated in inflammatory responses and constitute a high percentage of the migrating cells to inflamed tissues. They constitutively express VPAC1 and PAC1, and when exposed to inflammatory stimulus express VPAC2. The effect of VIP and PACAP on macrophage function has been repeatedly demonstrated. In unstimulated macrophages, VIP and PACAP increase IL-6 (interleukin 6) production through activation of the PKA and PKC pathways ([@B140], [@B141]). In contrast, it was reported that they inhibited the production of pro-inflammatory TNFα (tumour necrosis factor α), IL-6 and IL-12 in macrophage cultures in response to LPS (lipopolysaccharide) ([@B140]; [@B50], [@B51]). The negative effect on TNFα and other macrophage derived pro-inflammatory mediators (IL-12, IFNγ and NO) appeared to be mediated through the constitutively expressed VPAC1, although the inducible expressed VPAC2 could also participate ([@B43]). More recently, both peptides were shown to increase the synthesis and release of anti-inflammatory molecules like IL-10 and the IL-1Rα (IL-1 receptor antagonist), leading to a suppression of inflammatory responses ([@B49]). Finally, it has been reported that VIP and PACAP inhibit the production of several macrophage-derived chemokines such as MIP-2 (macrophage inflammatory protein 2), KC (keratinocyte chemoattractant) (IL-8), MIP-1α, MIP-1β, MCP-1 (monocyte chemoattractant protein 1) and RANTES (regulated upon activation, normal T-cell expressed and secreted), produced by LPS-activated macrophages ([@B44]).

APC/T-cell function
-------------------

T-lymphocyte differentiation is finely orchestrated by APCs through co-stimulatory molecules and the production of specific APC cytokines. Thus, Th cells differentiate upon antigen presentation into four main cell subsets named Th1, Th2, Th17 and adaptive (also called inducible) regulatory T-cells ([@B227]). Interestingly, *in vitro* studies showed that both neuropeptides were able to modify via VPAC1 receptors the expression of the APC co-stimulatory molecules B7.1 and B7.2 (or also called CD80/CD86) ([@B47], [@B52], [@B43]). For example, in resting macrophage cultures, VIP and PACAP promoted B7.2, but not B7.1, expression. In contrast, both peptides were shown to inhibit *in vivo* and *in vitro* the expression of B7.1 and B7.2 of LPS/IFNγ-activated macrophages ([@B47], [@B52], [@B43]). VIP and PACAP also appear to regulate the ability of DCs to activate T-cells ([@B58]). Indeed, in BM (bone marrow)-derived DCs, they up-regulated, via VPAC1, CD86 (B7.2) expression, and enabled them to stimulate T-cell proliferation and differentiation into Th2 effectors *in vivo* and *in vitro* ([@B43], [@B58]). In contrast, VIP/PACAP down-regulated CD80/CD86 (B7.1/B7.2) expression in LPS-stimulated DC cells and strongly reduced their capacity to stimulate T-cell proliferation and to secrete Th1 and Th2 cytokines. More importantly, related to these results, it has been shown that both human and murine DCs generated *in vitro* in the presence of VIP exhibited a 'tolerogenic' phenotype characterized as CD11c^low^CD45RB^high^ with the absence of CD80, CD86 and CD40 expression and ability to secrete high amount of the anti-inflammatory IL-10 cytokine after LPS stimulation. Remarkably, these VIP-induced tolerogenic DCs promoted the generation of Treg cells *in vivo* and *in vitro* ([@B59]; [@B83]).

T-cell function (reviewed in [@B57])
------------------------------------

VIP/PACAP and their GPCRs also appear to play an important role in many aspects of T-cell-dependent immunity, imperative to control infectious, autoimmune diseases and organ transplant rejection. On resting CD4^+^ T-cells, VPAC1 is expressed constitutively, whereas upon activation by anti-CD3 and anti-CD28 antibodies, VPAC1 is down-regulated while VPAC2 is induced ([@B127]). Interestingly, although most of the Th differentiation occurs via APC interaction as discussed above, a few *in vivo* and *in vitro* studies suggested that VIP and PACAP may in some cases, promote Th2 responses by regulating Th2-specific transcription factors, cytokine responses, proliferation, survival and chemotaxis ([@B55]; [@B213]). VPAC 1 and VPAC2 receptors may be involved in these actions. For example, it was shown that activated CD4^+^ T-cells expressed VPAC2 during differentiation to the Th2 phenotype, suggesting VPAC2 as a modulator for Th2 phenotype. On the other hand, VIP and PACAP via VPAC1 down-regulated *in vivo* and *in vitro* the production of CXCL10 (CXC chemokine ligand 10; IP-10) and up-regulated CCL22 (CC chemokine ligand 22) \[MDC (macrophage-derived chemokine)\], purported to be Th1- and Th2-specific chemokines respectively. This might lead to the preferential recruitment of the anti-inflammatory Th2 cell population ([@B112]; [@B56]).

VIP/PACAP effects on human T-cell function in MS
------------------------------------------------

The dynamics of VPAC receptor expression in peripheral blood T-lymphocytes from MS patients compared with healthy controls has been investigated ([@B194]). Similar to what had been shown previously for mouse lymphocytes, resting human T-cells from both MS patients and controls expressed high levels of VPAC1, but very low levels of VPAC2. Like in mice ([@B215]; [@B215]), when lymphocytes from either group were activated *in vitro* with anti-CD3 and anti-CD28 antibodies, VPAC1 expression was significantly down-regulated. This decrease in VPAC1 expression was compensated by a strong up-regulation of the VPAC2 receptor in healthy control lymphocytes, whereas the induction was severely impaired in MS patients ([@B194]). Interestingly, while CD4^+^ lymphocytes from healthy controls were able in the presence of VIP, to polarize into a Th2 phenotype with increased expression of the Th2-associated transcription factor Stat-6, this VIP effect was significantly dampened in MS patients, which could be due to the aberrant expression of its receptors ([@B194]).

VIP and PACAP as therapeutic agents in EAE ([Figure 2](#F2){ref-type="fig"})
----------------------------------------------------------------------------

![Potential effects of VIP and PACAP in EAE, a mouse MS model\
This is a schematic representation of the EAE-mediated immune response with a focus on APCs and T-cells. Briefly, after EAE induction, APCs present in the periphery of the MOG antigen to Th progenitors (Thp) which subsequently differentiate into Th1 or Th17 cell subsets. T effector Th1 and Th17 cells, so-called encephalitogenic Th cells, migrate towards the CNS crossing the blood−brain barrier (BBB). In the CNS, once re-activated by microglia/APC cells, Th1 and Th17 cells proliferate and secrete IFN-γ and IL-17 respectively, mounting a robust pro-inflammatory immune response against endogenous myelin that involves the secretion of multiple pro-inflammatory cytokines and chemokines. This leads to the recruitment of increasing numbers of immune cells, which amplifies the pro-inflammatory response. Ultimately, demyelination and neurodegeneration events occur, leading to the development of EAE symptoms. Due to their potent immunomodulatory and neuroprotective functions, VIP and PACAP can potentially act both in the periphery and the CNS to reduce and block the EAE pathogenesis. In the periphery, both peptides have been shown to inhibit Th1 and Th17 activities, while stimulating anti-inflammatory response by favouring Th2 and Treg generation. In the CNS, VIP and PACAP down-regulate T-cell re-activation and promote neuroprotection and neurorepair. These two phenomena lead to the suppression of EAE symptoms.](an003e065f02){#F2}

Based on the substantial success of systemic administrations of VIP and PACAP in other animal models of chronic inflammatory disease such as rheumatoid arthritis ([@B3]; [@B44]) and Crohn\'s disease ([@B2]), investigators have begun to examine whether or not these peptides might have efficacy in the EAE model of MS. For instance, in the earliest report, the effects of PACAP on MOG~35--55~ (myelin oligodendrocyte glycoprotein 35--55)-induced EAE were examined in C57BL/6 mice ([@B120]). Intraperitoneal administration of PACAP every other day after immunization with MOG ameliorated both the clinical and pathological manifestations of EAE. Splenocyte cultures from mice treated with PACAP exhibited significantly reduced MOG-specific Th1 IFNγ production. *In vitro* analysis revealed that PACAP suppressed the production of inflammatory cytokines, including TNFα, IL-1β and IL-12, and expression of the co-stimulatory factor B7.2 on macrophages and microglia. The authors suggested that PACAP suppressed induction of EAE primarily via suppression of APC function and inflammatory cytokine production. Other work focused on the therapeutic action of VIP in EAE. In these studies, the clinical and pathological scores in chronic MOG~35-55~-induced EAE in C57BL/6 mice were dramatically reduced by a 3-day treatment with VIP begun before or after the onset of EAE ([@B84]). Three-day treatment with either VIP or PACAP was also found to ameliorate EAE in a relapsing-remitting model (PLP139-151-induced SJL/J mice), with a blockade of symptoms lasting 60 days. The reduction of EAE and decreased inflammation after VIP administration was associated with decreased spinal cord levels of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, IL-18 and IL-12), enzymes \[iNOS (inducible nitric oxide synthase)\], chemokines (RANTES, MIP-1, MIP-2, MCP-1 and IP-10) and CCRs (CC chemokine receptors; CCR-1, CCR-2 and CCR-5) and increased levels of the anti-inflammatory cytokines IL-10, IL-1Ra and TGFβ (transforming growth factor β). The latter inductions occurred despite a 4-fold reduction in the number of inflammatory cells in the spinal cord as detected by FACS. Lymph nodes from VIP-treated mice showed reduced antigen-induced proliferation, and lower and higher production of Th1 and Th2 cytokine respectively.

VIP and PACAP as potential modulators of Treg and Th17 production and activity: significance in EAE ([Figure 2](#F2){ref-type="fig"})
-------------------------------------------------------------------------------------------------------------------------------------

As previously discussed, these peptides have formally been thought to act primarily via VPAC receptors by inhibiting macrophage activity and skewing Th1/Th2 responses in models of autoimmune diseases. However, with the increased interest in Treg cells in autoimmunity, and the discovery that many autoimmune diseases seem to be driven primarily by Th17 responses, emerging data indicated that VIP and PACAP might regulate the production or expansion of regulatory T-cells and Th17 responses. In the context of the EAE model, the administration of VIP to mice resulted in the expansion of the CD4^+^CD25^+^Foxp3^+^ expressing T-cells (Tregs) in the periphery and the nervous system, which were shown to inhibit encephalitogenic T-cell activation ([@B69]). VIP was also reported to enhance the suppressive efficiency of Tregs on a per cell basis. In adoptive transfer experiments, VIP-generated CD4^+^CD25^+^ Tregs were found to transfer suppression and significantly ameliorate the progression of the disease. Conversely, CD4^+^ T-cells from VIP-treated EAE mice did not transfer disease, whereas CD4^+^CD25^+^-depleted T-cells from VIP-treated EAE mice did. In another study, the same investigators studied potential mechanisms by which VIP induced expansion of Tregs ([@B37]). In the *ex vivo* experiments, mice with evolving EAE were injected with DCs generated from cultures of syngenic BM cells in the presence or absence of VIP (cells were termed DC~VIP~ and DC~con~ respectively). Injection of DC~VIP~ but not DC~con~ was found to reduce EAE symptoms in association with a decreased ability of draining lymph node cultures to proliferate and produce IFNγ cytokine in response to autoantigen. Moreover, injection of DC~VIP~-induced MOG-specific regulatory T-cells, but not DC~con~-induced cells, significantly attenuated EAE. These results suggest that the induction and/or activation of regulatory T-cells via the production of tolerogenic DCs may be a mechanism by which exogenous VIP (or perhaps PACAP) alleviates EAE. No studies have specifically examined the role of VIP or PACAP in Th17 cells in EAE or other inflammatory disease models, although IL-17 gene expression was found to be reduced in VIP-treated against untreated mice in CIA (collagen-induced arthritis; [@B113]) and in colonic extracts in a chemical-induced colitis model ([@B1]).

One of the problems that could limit the use of VIP as a therapeutic agent in MS or other diseases is the short biological half-life (*t*~½~) of the peptide. This latter topic will be discussed later in the 'Pharmacology and drug design' section. In order to sustain beneficial VIP levels in the organism, the group of [@B202] tested in mice a strategy based on the transfer of DCs transduced with vectors expressing VIP (lenti-VIP DCs). The intravenous transfer of these cells to mice with EAE reduced the clinical symptoms of the disease as well as the mRNA expression of the key pro-inflammatory cytokines IL-1β, TNFα and IL-6. After inoculation, these cells were found in several organs such as the liver, lung, lymph nodes and spleen. The mechanisms for the therapeutic actions of these cells could be double. On the one hand, before transfer, the lenti-VIP DCs were functionally 'tolerogenic'. On the other hand, the serum levels of VIP in these mice assessed 48 h after inoculation were 3-fold higher than those in non-injected mice, demonstrating that transfer of these cells resulted in systemic levels of VIP, leading to a more robust inhibition of the inflammatory response.

GENETIC MANIPULATION OF VIP, PACAP AND THEIR RECEPTORS IN MICE AND THEIR APPLICATION TO INFLAMMATORY DISEASE MODELS
===================================================================================================================

VIP KO (knockout) and PACAP KO mice in EAE
------------------------------------------

As for many peptides and their cognate receptors, clear insights into their physiological roles have recently been gained through the use of genetically engineered mice. These have been used to investigate immunomodulatory actions of endogenous VIP and PACAP. For example, although the mechanism is still uncertain, we showed that the severity of MOG~35--55~-induced EAE is increased in PACAP-deficient mice in association with enhanced Th1/Th17 and diminished Th2 responses in the spinal cord, indicating that endogenous PACAP is protective in this model of autoimmune disease ([@B196]). Moreover, we found a significant reduction in the abundance of Tregs in the lymph nodes of PACAP KO mice during the recovery phase of the disease. It has been experimentally demonstrated in this model of EAE that natural, but not inducible, Tregs are involved in the recovery phase ([@B123]). Thus, the results from PACAP KO mice suggest a new role for PACAP as an endogenous modulator of natural Treg expansion. We also recently studied the response of VIP KO mice to EAE induction ([@B5]). In contrast to PACAP KO mice, VIP KO mice were highly resistant to EAE at the clinical and histopathological levels. Supporting this phenotype, the levels of multiple pro-inflammatory cytokines in the spinal cord were strikingly reduced in the KO mice. The lack of inflammatory disease in these mice precluded an investigation of how VIP loss affected Treg expansion. Interestingly, *ex vivo* antigen-rechallenge studies suggested that the immunization phase of EAE was unimpaired in VIP KO mice. Moreover, immune cells isolated from MOG-immunized VIP KO mice had encephalitogenic properties as exhibited by the fact that they were capable of inducing EAE when adoptively transferred to WT (wild-type) hosts. Although the mechanism for the EAE resistance of VIP KO mice remains to be elucidated, immune cells were found to be trapped in the meninges of the brain and spinal cords, and failed to invade the CNS parenchyma of VIP KO mice, suggesting a defect in immune cell migration.

VIP/PACAP receptor KO mice in inflammatory disease models
---------------------------------------------------------

In addition to mice deficient in VIP or PACAP, the development of receptor KO mice has provided valuable tools to elucidate the mechanisms responsible for the actions of these peptides in the immune system. Although not yet tested for EAE susceptibility, they have been subjected to different models of inflammatory diseases. For example, PAC1 KO mice showed increased mortality after LPS injection in comparison with their WT counterparts, a finding linked to an overstimulation of the IL-6-dependent coagulation and chemotaxis cascades ([@B139], [@B142]). Inflammatory phenotypes of VPAC2 receptor KO mice have also been examined. In these mice, anti-CD3/CD28 stimulation of purified splenic CD4^+^ T resulted in 3-fold higher levels of IL-2 and IFNγ than in WT mice and 90% lower levels of IL-4 ([@B80]). These results, along with a finding of relative resistance to cutaneous anaphylaxis and an enhanced hapten-evoked cutaneous DTH (delayed-type hypersensitivity) response in KO mice, suggested that loss of VPAC2 leads to a state of enhanced delayed-type hypersensitivity and depressed immediate-type hypersensitivity ([@B80]). Conversely, transgenic mice overexpressing VPAC2 receptors specifically in CD4^+^ T-cells exhibited increased Th2/Th1 cytokine profiles and alterations in delayed against immediate hypersensitivity ([@B214]). The studies reinforce the *in vivo* and *in vitro* data suggesting that PACAP and VIP serve to promote and/or reinforce Th2-type responses at the expense of Th1.

*In vitro* studies by [@B223] addressed the complexity of VPAC1 and VPAC2 signalling effects in lymphocyte differentiation. Interestingly, *in vitro* treatment of isolated CD4^+^ cells with VIP in the presence of TGFβ promoted the generation of T-cells with a Th17-like phenotype, producing IL-17 and IL-22 but not IL-21. It was inferred that this effect was mediated by VPAC1 because this is the main receptor expressed in resting lymphocytes. Moreover, in CD4^+^ cells from VPAC2 KO mice, where the expression of VPAC1 is enhanced, Th17-like polarization was even stronger. This suggests that VIP signalling through VPAC1 receptor can, at least in some contexts, promote a potential pro-inflammatory T-cell phenotype. Studies using the model of DSS (dextran sodium sulfate) colitis supported this possibility ([@B222]), because VPAC1 KO mice exhibited a milder disease than WT controls, whereas VPAC2 KO mice exhibited enhanced colitis after DSS treatment.

Therapeutic actions of VIP/PACAP in other mouse models of inflammatory disease
------------------------------------------------------------------------------

VIP and PACAP have also been shown to have beneficial therapeutic effects in mouse models of rheumatoid arthritis, septic shock and Crohn\'s Disease. CIA exhibits most of the clinical and histological features of rheumatoid arthritis in humans. Either VIP or PACAP, injected intraperitoneally every day or every other day, reduced dramatically the incidence and the severity of arthritis, even when they were administered in the late stages of the disease ([@B3]; [@B44]). After treatment, paw joints of the VIP- and PACAP-treated animals, unlike controls, showed no evident signs of inflammation (redness and swelling), and in the histological study of the joint tissue there was no *pannus* formation in the treated animals, and the joint structure was preserved. Administration of VIP or PACAP was found to inhibit both the inflammatory and the autoimmune (Th1) components of the disease and to promote a Th2 cytokine profile. In another model, VIP and PACAP were also found to protect against endotoxin-induced lethality and prevent septic shock-associated histopathological alterations ([@B48]). Finally, in a chemical-induced colitis model, VIP was found reduce the clinical and histopathological severity, abrogating body weight loss, diarrhoea and macroscopic and microscopic intestinal inflammation ([@B2]). The therapeutic effects were associated with down-regulation of both inflammatory and Th1-driven autoimmune responses, and an up-regulation of Th2 anti-inflammatory cytokines ([@B2]). Thus, PACAP and VIP have emerged as candidates for the treatment of autoimmune and other inflammatory diseases, especially those associated with an overproduction of Th1 cytokines.

Taken together, through their actions on cytokines, chemokines, cell adhesion molecules, and co-stimulatory molecules produced or expressed by activated APCs, and through its direct and/or indirect effects on Th cell responses, VIP and PACAP appear as important endogenous immunomodulatory molecules that exert mainly protective anti-inflammatory actions in many different models of autoimmune diseases.

OTHER VIP/PACAP ACTIONS RELEVANT TO MULTIPLE SCLEROSIS
======================================================

Potent neuroprotective properties
---------------------------------

Evidence from both *in vitro* and *in vivo* experiments described below suggest that VIP and PACAP may promote neural cell proliferation, survival and axon regeneration as well as oligodendrocyte progenitor proliferation and maturation. However, despite their homologies, it is apparent that in most cases, PACAP was shown to be significantly more potent than VIP. The latter may be due to the fact that many of these growth factor-like actions are mediated by PAC1, the PACAP-preferring receptor.

Growth factor-like actions of PACAP
-----------------------------------

PACAP has been shown to exhibit a variety of trophic or growth factor-like actions on cultured neurons and glia subtypes. Early studies showed that PACAP stimulated the outgrowth of neurites from PC12 cells ([@B60]). It was later shown in cultured cortical precursor cells from E13 rats (E is embryonic day) that PACAP induced cell cycle withdrawal and promoted the transition from proliferation to differentiation ([@B136]). PACAP also potently increased cAMP levels in cultured hindbrain neuroepithelial cells from E10.5 mice and down-regulated the expression of the sonic hedgehog-dependent target gene gli-1 ([@B219]). In other work, it was reported that PACAP increased mitosis in cultured embryonic SCG (superior cervical ganglion) precursors and potently enhanced precursor survival via the PACAP-preferring PAC1 receptor ([@B62]). Furthermore, PACAP promoted SCG neuronal differentiation, increased neurite outgrowth and enhanced expression of the neurotrophin receptors trkC and trkA ([@B62]). PACAP effects on SCG precursors were shown to be mediated by PAC1, via increased intracellular second messengers including cAMP and phosphatidylinositol as well as Ca^2+^. This findings in SCG cultures explained early studies demonstrating that high concentrations of VIP stimulate mitosis, promote neurite outgrowth and enhance survival of sympathetic neuroblasts in culture ([@B167]).

PACAP has been reported to prevent PCD (programmed cell death) in cultured CGCs (cerebellar granule cells; [@B212]; [@B209]), as well as apoptosis induced by different neurotoxins such as ethanol ([@B211]), H~2~O~2~ and H~2~O~2~ during oxidative stress ([@B210]), and ceramides ([@B207]). Using PC12 cells, it was shown that PACAP provided protection against cytotoxicity of β-amyloid, a key factor in AD (Alzheimer\'s disease; [@B158]) and of human prion protein fragment 106--126 \[PrP(106--126)\] ([@B160]). In purified embryonic rat cortical cultures, PACAP suppressed glutamate-induced neuronal cell death in up to 50% of the cells compared with control ([@B150]). Moreover, PACAP was shown to protect cerebral cortical neurons from neuronal loss triggered by gp120, the envelope glycoprotein from the HIV ([@B25]). These *in vitro* data supported those performed *in vivo*. For example, in the ischaemia-induced PMCAO (permanent middle cerebral artery occlusion) model, PACAP, administered to rats either before ([@B174]) or after the occlusion ([@B173]), significantly reduced the infarct size. Likewise, in a model of Parkinson\'s disease, PACAP treatment effectively protected the dopaminergic nigrostriatal neurons from apoptotic death, and resulted in reduced neurological deficits and more rapid amelioration of behavioural abnormalities ([@B172]). Moreover, PACAP increased neuronal survival after spinal cord compression ([@B36]), suggesting that PACAP could have beneficial effects in tissue restoration after nerve injury. Consistent with this hypothesis, PACAP mRNA was up-regulated for as long as 30 days after facial motor neuron axotomy ([@B226]) and nerve regeneration was impaired in PACAP KO animals ([@B6]).

In most of the aforementioned studies, the effects of PACAP were mediated through PAC1 receptor and linked to the PKA pathway ([@B150]; [@B160]; [@B210], [@B207]). However, it is clear that neuroprotective actions include, but are not limited to, cAMP-mediated processes. Thus, MAPK pathways also contribute to the neuroprotective action of PACAP ([@B160]; [@B210], [@B207]). For example, it was indicated that under brain ischaemic stress, PACAP acted in neurons through the inhibition of JNK (c-Jun N-terminal kinase)/SAPK (stress-activated protein kinase) and p38 signalling pathways ([@B65]). Furthermore, this latter action was also accompanied by blockade of DNA fragmentation and inhibition of caspase-3 activation, the key enzyme of the apoptosis process ([@B209], [@B210], [@B207]; [@B158]). The effect of PACAP was mimicked by cAMP analogues, and abrogated by inhibitors of PKA and PKC, which implies that the process of caspase-3 de-activation may be mediated via both the AC/cAMP/PKA and PLC/IP3/DAG (diacylglycerol)/PKC signalling pathways ([@B209]; [@B158]). It was observed that PACAP, in addition to direct stimulation of neurons, can also affect them indirectly. For example, in the ischaemic region, the peptide stimulated astrocytes that secrete IL-6 into the cerebrospinal fluid. IL-6, similar to PACAP, inhibited the activation of JNK/SAPK in neuronal cells ([@B182]). Finally, it has been suggested that PACAP protects neurons from death after ischaemia through induction of IL-6 and consequent activation of the STAT3 and ERK (extracellular-signal-regulated kinase) signalling pathways ([@B157]).

Growth factor-like actions of PACAP are reviewed in [@B41] and [@B181].

Growth factor-like actions of VIP
---------------------------------

Well before the discovery of PACAP in 1989, the first report of VIP neuroprotection appeared, showing that subnanomolar concentrations of VIP rescued neurons in primary embryonic spinal cord cultures deprived of electrical activity ([@B20]; [@B19]). Later, it was reported that VIP provides neuronal defence by inducing the synthesis and secretion of diverse neuroprotective glia-derived trophic substances such as nerve growth factor ([@B104]), cytokines ([@B26]), chemokines ([@B24]), protease nexin-1 ([@B71]) and particularly ADNF (activity-dependent neurotrophic factor; [@B22]) and ADNP (activity-dependent neuroprotective protein; [@B185]). ADNF is reported to be a potent neuroprotective astroglia-derived factor ([@B22]). Two fragments of ADNF, ADNF-14 and ADNF-9, prevented cell death induced by gp120 (HIV envelope protein), β-amyloid (fragment 25--35) and activation of glutamate NMDA (*N*-methyl-[d]{.smallcaps}-aspartate) type receptors, being effective at femtomolar concentrations ([@B22], [@B21], [@B23], [@B27]). Moreover, ADNF-9 was reported to exhibit greater potency and efficacy in preventing cell death than ADNF-14 or the parent protein ADNF ([@B22], [@B27]). In addition, experimental data showed that ADNP mRNA concentration in the rat astrocytes was increased 2--3-fold after a short exposure to VIP ([@B10]; [@B94]). In cerebral cortical cultures exposed to TTX (tetrodotoxin), gp120, β-amyloid or NMDA, NAP (neutrophil-activating protein), an 8-amino acid fragment of ADNP, exhibited stronger neuroprotective efficacy than ADNF-9 itself ([@B94]).

*In vivo* studies have corroborated the *in vitro* actions of ADNF-9 and NAP described as follows: (i) ADNF-9 has been shown to protect against gp120 in a model mimicking intrauterine growth retardation which is common in infants born to HIV-positive mothers ([@B61]) and (ii) NAP improved the developmental reflexes and prevented short-term memory deficits in a model of ApoE (apolipoprotein E)-deficient mice for AD ([@B10]). Other investigations have demonstrated that ADNF-9 may act as an endogenous growth-regulating factor during embryonic development ([@B103]). NAP and ADNF-9 prevented cellular oxidative stress in a mouse model of fetal alcohol syndrome where pregnant mice were exposed to ethanol during mid-gestation (E8) ([@B189]). Finally, in the PMCAO model, NAP provided a significant protection against neuronal damage associated with stroke by inhibiting key factors inducing apoptosis of neuronal cells ([@B131]).

In other studies, VIP was shown to inhibit pro-inflammatory mediators released by activated microglia, which purportedly contribute to the neuronal cell death in neurodegenerative disorders. VIP also significantly blocked the microglia activation and production of neurotoxic factors including TNFα, IL-1β and NO (nitric oxide) in a model of Parkinson\'s disease and brain trauma ([@B45], [@B46]). Recently, it has been demonstrated that VIP has a unique and potent neuroprotective action of the perinatal white matter against excitotoxic insults that is not recapitulated by PACAP ([@B96]). Moreover, when given systemically, VIP and stable VIP agonists appeared to promote axonal regrowth in this model through VPAC2 receptors and PKC and MAPK pathways ([@B163]). On the other hand, VIP cytoprotective effects in some contexts have been attributed to action on the PAC1, specifically on the Hop2 splice variant of PAC1 ([@B166]). For example, the Hop2 splice variant has been shown to be expressed and prevent toxicity during oxidative stress ([@B166]) and ischaemic injury ([@B181]).

Growth factor-like actions of VIP are reviewed in [@B218] and [@B41].

Taken together, interestingly, unlike the most current and emerging therapeutic agents designed for the treatment of MS, the therapeutic mechanisms of VIP and PACAP peptides are not only delimited to their remarkable anti-inflammatory function but also to their potent growth factor-like and specifically neuroprotective effects.

PHARMACOLOGY AND DRUG DESIGN
============================

Based on the above observations, VIP, PACAP, and their receptors are currently being considered as therapeutic targets for MS and other chronic inflammatory disorders. However, a major drawback with the use of native peptides in therapy is their high sensitivity to protease degradation and ultimately their bioavailability. Indeed, VIP is a 28-amino acid peptide that undergoes rapid degradation *in vivo* with a *t*~½~ of less than 1 min in the blood ([@B66]). Moreover, the 38-residue isoform of PACAP displays a *t*~½~ of less than 5 min in isolated human plasma, whereas PACAP27 is relatively resistant to degradation *in vitro* ([@B15]). This observation suggests that the 28--38 region is essential for the degradation of PACAP ([@B15]). To circumvent this problem, recent data indicated that acetylation of the N-terminal end of PACAP confers resistance to DPPIV (dipeptidyl peptidase IV) ([@B15]). Other strategies have been developed to protect the peptide against degradation by insertion of VIP into micelles or nanoparticles ([@B70]; [@B162]). A second major obstacle that reduces the therapeutic use of VIP and PACAP in humans is their relative ability to act on multiple VIP and PACAP receptor subtypes, or when given at high doses even on other class B GPCRs ([@B126]; [@B208]). These cross-interactions may result in peripheral side effects induced by VIP and PACAP ([@B126]; [@B208]). Strategies to overcome these compromising conditions include the development of specific and metabolically stable ligands of VPAC1, VPAC2, and PAC1 receptors.

Regarding VPAC receptors, most of the structure--activity relationship analyses so far have been carried out with VIP and PACAP derivatives and have contributed to the development of valuable pharmacological tools that discriminate between VPAC1 and VPAC2 ([@B124]; [@B126]; [@B208]). For instance, the PACAP (6--38) fragment exhibits a 15-fold higher affinity for VPAC2 than for VPAC1 ([@B90]), whereas PACAP (1--25) possesses a 66-fold higher affinity for VPAC1 than for VPAC2 ([@B89]). Thus, a complete alanine scanning ([@B156]; [@B107], [@B108]) as well as D-amino acid scanning of VIP ([@B107], [@B108]) allowed the rationally design of selective, high affinity and metabolically stable analogues of VPAC receptors. The most potent and specific peptide agonist for VPAC1 receptor currently available is \[Ala^11,22,28^\]-VIP ([@B156]). Moreover, two analogues (\[Ala^2,8,9,11,19,22,24,25,27,28^\])VIP and \[Ala^2,8,9,11,19,24−28^\]VIP) were found to have high selectivity for hVPAC1 ([@B159]). \[Ala^2,8,9,16,19,24,25^\]VIP agonist for VPAC2 was much more metabolically stable than VIP ([@B159]). With regard to antagonists, \[Ac-His^1^D-Phe^2^,K^15^R^16^L^27^\]VIP(3--7)/GRF(8--27) (also called PG 97--269) is a selective high-affinity antagonist of the VPAC1 receptor ([@B88]). Regarding the VPAC2 receptor, the cyclic peptide analogue of VIP \[Ac-Glu^8^OCH3-Tyr^10^Lys^12^Nle^17^Ala^19^Asp^25^Leu^26^-Lys^27^,28-VIP(cyclo 21--25)\] or Ro 25--1392 is a potent and selective agonist ([@B221]). Likewise, the VIP analogue RO 25--1553, that possesses a C-terminally extended tail and an α-helix-stabilizing lactam bridge between residues 21 and 25, behaves as a selective VPAC2 agonist ([@B14]; [@B91]). In our opinion, there is still no highly selective VPAC2 receptor antagonist because PG 99-465, a VIP analogue that antagonizes VIP action on the VPAC2 receptor, has significant agonist activity on human VPAC1 receptor ([@B149]). Together, these data suggest that the C-terminal helical domains of PACAP and VIP are important for the binding affinity towards VPAC2, whereas, conversely, VPAC1 seems tolerant to deletion at the C terminus.

Regarding PAC1 receptors, as for VPAC receptors, an extensive set of structure--activity relationship studies was performed combining alanine scanning, directed mutagenesis, deletion and/or chimaerism analyses. Thus, numerous PACAP analogues have been synthesized to identify the molecular determinants responsible for the recognition and activation of the receptors ([@B16]). In 1991, a natural 61-amino acid vasodilator polypeptide called maxadilan was isolated from the salivary gland extracts of the blood-feeding sand fly ([@B134]). Later, although there is a lack of primary sequence homology with PACAP, maxadilan was definitively characterized as a potent and highly selective agonist of PAC1 ([@B151]; [@B133]). A shortened maxadilan synthetic analogue, termed as M65, in which the amino acid sequence 25--41 was deleted, acts as a specific PAC1 antagonist ([@B203]; [@B152]; [@B133]). As previously reported, the N-terminal region of PACAP seems to play a crucial role for the biological activity of the peptide ([@B92]; [@B175]; [@B12]). Indeed, gradual deletion of the N-terminal residues of PACAP38 showed that PACAP(6--38) is a potent antagonist ([@B176]). Moreover, the chemical modification of PACAP38 led to the development of \[R^15,^ ^20,^ ^21^,L^17^\]-PACAP38 which exhibited enhanced stability with a 42% reduction in degradation kinetics compared with that of PACAP38 and biological activity ([@B159]). As discussed, PACAP27 and VIP possess a high degree of sequence homology (68%). However, VIP is not able to bind to PAC1 efficiently. Because sequence differences between VIP and PACAP are restricted to regions 4--13 and 24--28, the PAC1 selectivity should reside within these two regions. Synthesis and pharmacological characterization of VIP/PACAP chimaeras showed that the selectivity of PAC1 towards PACAP implicates not the C-terminal domain but rather the chemical motifs of the 4--13 region ([@B179]; [@B161]).

Although a multitude selective peptide agonists and, to a lesser extent, antagonists have already been described, the development of potent small non-peptide molecules acting on VIP/PACAP receptors is a challenging goal. Indeed, the hydrazides have been discovered recently as specific antagonist for PAC1 receptor, and are the first potent small molecule antagonists ever reported for VIP/PACAP receptors ([@B11]). In parallel, the recent finding of N-cap motifs which orientate the N-terminal part of members of VIP/secretin family, and are presumably involved in receptor activation, may serve as a template for a new rational drug design. Thus, the further structural analyses and structure--activity relationship studies of the receptors should be very helpful to understand the mechanism of activation of the VIP/PACAP receptors, and ultimately for the design of new non-peptide drugs targeting VIP and PACAP receptors.

CONCLUSION
==========

Current and emerging therapeutic agents have so far been primarily designed to suppress the immune response in MS patients. They are capable of reducing the severity of early stage MS and slowing its progression, but without having significant action during the secondary phase of the disorder. Thus, it is important to find new promising therapeutic tools acting also on the neurodegenerative aspect of MS physiopathology. VIP and PACAP exhibit not only a potent anti-inflammatory action, but also remarkable neurotrophic and neuroprotective actions. These peptides and their receptors may modulate both the excess of inflammation and the neurodegenerative processes associated with MS. Recently, the development of VIP and PACAP-related drugs in the treatment of multiple sclerosis has become a new challenge.
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